Document:

<PAGE>   1
                                                                    EXHIBIT 10.5

                        MEDICAL COLLEGE OF HAMPTON ROADS
                                      D/B/A
                         EASTERN VIRGINIA MEDICAL SCHOOL

                           RESEARCH FUNDING AGREEMENT
<PAGE>   2

                           RESEARCH FUNDING AGREEMENT

         This Research Funding Agreement (the "Agreement") is entered into and
made as of the 31st day of January, 2000, by and between MEDICAL COLLEGE OF
HAMPTON ROADS d/b/a EASTERN VIRGINIA MEDICAL SCHOOL ("EVMS"), whose mailing
address is P.O. Box 1980, Norfolk, Virginia 23501, and GMP EndoTherapeutics,
Inc. ("GMP"), whose mailing address is One East Broward Blvd., Suite 1701, Fort
Lauderdale, Florida 33301 with respect to the facts set forth below.

                                    RECITALS

         A.       EVMS is engaged in scientific biomedical and biochemical
                  research, including research relating to animal and human
                  pancreatic beta cell growth factors, islet neogenesis
                  associated proteins ("INGAP"), INGAP genes, reagents for
                  regulating INGAP expression or activity and uses thereof, as
                  more particularly described herein.

         B.       EVMS and McGill University ("McGill") are the owners of
                  certain patents and patent applications, including any
                  divisions, continuations, reissues, reexaminations,
                  continuations-in-part and international and foreign
                  applications and patents corresponding thereto and issued
                  thereon (hereinafter collectively referred to as the
                  "Patents") which are being licensed to GMP under a license
                  agreement of even date between EVMS, McGill and GMP (the
                  "License Agreement").

         C.       GMP desires to provide certain funding as part of the EVMS
                  research activities described above and which will assist the
                  parties in the successful approval and commercialization of
                  products that are covered in whole or in part by the Patents.

         D.       EVMS has or shall have the exclusive right to convey the
                  ownership rights in and to any technology developed pursuant
                  to the research program described herein.

         E.       EVMS is willing to grant to GMP the right to acquire exclusive
                  ownership of technology arising from the Research Program
                  within the Field (as those terms are defined hereinbelow),
                  including the right to develop, market and sell products in
                  the Field, all as more particularly described herein.

                                                                               2
<PAGE>   3

                                    AGREEMENT

         NOW, THEREFORE, in consideration of the mutual covenants and conditions
outlined herein, EVMS and GMP hereby agree as follows:

         1.       DEFINITIONS

                  1.1      Agents. The term "Agents" shall mean employees,
                           students, consultants, and independent contractors or
                           other persons under the control or supervision of
                           EVMS or GMP, as applicable and their respective
                           subcontractors.

                  1.2      Confidential Information. The term "Confidential
                           Information" shall mean any and all proprietary
                           information owned or possessed by EVMS or GMP which
                           may be exchanged between the parties at any time and
                           from time to time during the term hereof. The fact
                           that a party may have marked or identified as
                           "Confidential" or "Proprietary" any specific
                           information shall be indicative that such party
                           believes such information to be confidential or
                           proprietary, but the failure to so mark information
                           shall not conclusively determine that such
                           information was or was not considered confidential
                           information by such party. Information shall not be
                           considered confidential to the extent that it:

                                    a.       Is publicly disclosed through no
                                             fault of any party hereto, either
                                             before or after it becomes known to
                                             the receiving party; or

                                    b.       Was known to the receiving party
                                             prior to the date of this
                                             Agreement, which knowledge was
                                             acquired independently and not from
                                             the other party hereto (including
                                             such party's employees); or

                                    c.       Is subsequently disclosed to the
                                             receiving party in good faith by a
                                             third party who has a right to make
                                             such disclosure; or

                                    d.       Has been published by a third party
                                             as a matter of right; or

                                    e.       Is independently developed by the
                                             receiving party.

                  1.3      Field. The term "Field" shall mean animal and human
                           pancreatic beta cell growth factors, islet neogenesis
                           associated proteins ("INGAP"), including peptides,
                           peptidomimetics, derivatives or analogs thereof;
                           INGAP genes, including nucleic acid fragments and
                           derivatives or analogs thereof; reagents for
                           regulating INGAP expression or activity and
                           therapeutic and diagnostic uses thereof.

                                                                               3
<PAGE>   4

                  1.4      Principal Investigator. The term "Principal
                           Investigator" shall mean the person identified in
                           Section 2.3 below, together with such replacement
                           persons selected in accordance with the provisions
                           thereof.

                  1.5      Proprietary Property. The term "Proprietary Property"
                           shall mean, any and all technology, discovered,
                           developed or otherwise arising during the term of
                           this Agreement, including without limitation, any
                           idea, data, compound, molecule, cell line, material,
                           know-how, technique, method, process, use,
                           composition, skill, Confidential Information, trade
                           secret or configuration of any kind, whether or not
                           any such information would be enforceable as a trade
                           secret, the copying of which would be enjoined or
                           restrained by a court as constituting copyright
                           infringement or unfair competition or would be
                           eligible for protection under the patent laws of the
                           United States or elsewhere.

                  1.6      Research Program. The term "Research Program" shall
                           mean the research program to be undertaken by EVMS
                           under the direction and control of the Principal
                           Investigator set forth in Section 2.3 hereof.

                  1.7      EVMS Technology. The term "EVMS Technology" shall
                           mean any Proprietary Property outside the Field
                           conceived or first reduced to practice, in whole or
                           in part by EVMS or EVMS Agents in the performance of
                           the Research Program during the term of this
                           Agreement, including any intellectual property within
                           the scope of the Research Program but outside the
                           Field developed by EVMS or EVMS Agents during the
                           term of this Agreement while rendering services to
                           GMP as a consultant or otherwise.

                  1.8      GMP Technology. The term "GMP Technology" shall mean
                           any Proprietary Property within the Field conceived
                           or first reduced to practice by EVMS or EVMS Agents
                           during the period such persons were working on
                           projects or activities funded by this Agreement, or
                           and Proprietary Property provided to EVMS or EVMS
                           Agents by GMP or its Agents.

                  Other capitalized terms used herein are as defined in the
         License Agreement.

                                                                               4
<PAGE>   5
*** CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES
    AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

         2.       CONDUCT AND FUNDING OF RESEARCH PROGRAM

                  2.1      Conduct of Research Program. EVMS hereby agrees to
                           conduct the Research Program in the Field subject to
                           the provisions of this Agreement. The research and
                           development activities to be conducted under this
                           Agreement shall include the work required to obtain
                           Registration Approval and commercial acceptance of
                           Licensed Products. The initial activities should
                           include animal experiments required to obtain
                           governmental approval for commercial use of the
                           Licensed Products and to obtain approval by the FDA
                           to initiate Phase I Clinical Trials. EVMS agrees to
                           conduct all research and experiments and reporting of
                           the same in accordance with the appropriate
                           governmental standards. It is contemplated that the
                           research conducted under this Agreement shall include
                           Phase I Clinical Trials and other phases of Clinical
                           Trials, subject to the requirements of Section 2.4
                           below, and governmental recognition of EVMS as an FDA
                           approved clinical site.

                  2.2      Funding of Research Program. GMP shall pay to EVMS a
                           total of  [***] to conduct the research program
                           contemplated by this Agreement. Such payments shall
                           be made in the amount of  [***] per month for a
                           period of [***] years. The GMP funding shall not be
                           used to pay for indirect costs or other EVMS overhead
                           costs. Payments shall be made monthly, on or before
                           the 10th day of each month.

                  2.3      Supervision of Research Program. EVMS agrees that the
                           Research Program at EVMS shall be conducted by or
                           under the direct supervision of the following
                           Principal Investigator: Dr. Aaron Vinik. In the event
                           that the Principal Investigator leaves EVMS, or
                           terminates his/her involvement in the Research
                           Program, EVMS shall use its best efforts to find a
                           replacement Principal Investigator acceptable to GMP,
                           which acceptance shall not be unreasonably withheld.
                           In the event that EVMS shall fail to appoint a
                           replacement Principal Investigator reasonably
                           acceptable to GMP, GMP shall have a right to
                           terminate this Agreement upon delivery to EVMS of
                           written notice of intent to terminate pursuant to
                           this Section 2.3, which notice must be delivered to
                           EVMS not less than 30 days nor more than 90 days
                           after delivery by EVMS to GMP of the name of the
                           replacement Principal Investigator. Such termination
                           shall be considered a termination under Section 7.4.2
                           below.

                  2.4      Clinical Trials. For any research by EVMS that
                           includes clinical research, the parties shall enter
                           into additional agreements regarding coverage for
                           medical care costs not covered by third party payors,
                           indemnification for EVMS, and reimbursement for
                           additional clinical trial costs on a per subject
                           basis. These additional agreements shall be
                           separately negotiated prior to the commencement of
                           any such trials.

                                                                               5
<PAGE>   6

                  2.5      Reports.

                           a.       EVMS agrees that its efforts hereunder
                                    include working with GMP to provide the
                                    necessary studies, reports, protocols,
                                    procedures, applications and other
                                    governmental requirements in the United
                                    States in order to achieve the approvals
                                    necessary to allow the commercial use of
                                    Licensed Products in animals and to initiate
                                    Phase I Clinical trials in humans.

                           b.       EVMS agrees to meet periodically with GMP
                                    representatives to review the research
                                    efforts being conducted and to be conducted
                                    by EVMS under the Research Program and to
                                    coordinate the efforts of both parties in
                                    obtaining the necessary governmental
                                    approvals for commercialization of Licensed
                                    Products for use in animals and humans. Such
                                    meeting shall be held at least quarterly
                                    during the course of this Agreement.

                           c.       EVMS agrees that within sixty (60) days
                                    following the last day of each calendar year
                                    during the term of this Agreement, EVMS
                                    shall furnish GMP with a written report
                                    summarizing the results of the research
                                    included within the scope of the Research
                                    Program during the immediately preceding
                                    calendar year conducted by EVMS.

                           d.       All information submitted by either party to
                                    the other as a result of the Research
                                    Program under this Agreement, whether
                                    written, oral, electronic, or in other form,
                                    and whether specifically marked confidential
                                    or not, is deemed Proprietary Property. If
                                    the Proprietary Property pertains to GMP
                                    Technology, it shall be deemed to be
                                    Proprietary Property belonging to GMP. If
                                    the Proprietary Property pertains to EVMS
                                    Technology, it shall be deemed to be
                                    Proprietary Property belonging to EVMS. GMP
                                    Proprietary Property will be used by EVMS
                                    only for the purpose of conducting its
                                    activities under this Agreement.

                           e.       EVMS Proprietary Property shall be used by
                                    GMP for the purposes of carrying out its
                                    obligations or performance under this
                                    Agreement and the License Agreement,
                                    including evaluating whether or not to
                                    exercise an option to obtain a license
                                    pursuant to Section 3 hereof, as and when
                                    such option is exercisable in accordance
                                    with the terms hereof.

                           f.       Neither party shall, during the term or
                                    after the termination hereof, use or
                                    disclose any of the Proprietary Property of
                                    the other party to any third party, unless
                                    and until (i) permitted to do so pursuant to
                                    the terms of any license agreement entered
                                    into by the parties, or (ii) such
                                    information no longer comes within the
                                    definition of

                                                                               6
<PAGE>   7

                                    "Confidential Information" hereunder and
                                    otherwise becomes available as public
                                    information.

         3.       OPTION FOR EXCLUSIVE LICENSE.

                  3.1      Grant of Option. Subject to the terms of this
                           Agreement, EVMS hereby grants to GMP an exclusive
                           option to acquire exclusive worldwide ownership
                           rights or licenses to make, have made, sell or use
                           EVMS Technology. Each such right or license shall be
                           to a specific application of EVMS Technology. Such
                           option shall be for the period and exercised as more
                           particularly described below.

                  3.2      Disclosure of Technology. As soon as reasonably
                           possible, either upon conception or reduction to
                           practice, as the case may be, of each and every
                           application of GMP Technology or EVMS Technology,
                           EVMS shall disclose the same in writing to GMP. Such
                           disclosure shall contain sufficient detail to enable
                           GMP to evaluate the significance of the Technology
                           and, if EVMS Technology, the advisability of
                           exercising the option granted hereunder with respect
                           to such EVMS Technology.

                  3.3      Option Period. GMP shall have a period of ninety (90)
                           days from receipt of the disclosure from EVMS
                           described in Section 3.2 within which to exercise its
                           option to obtain a license to a particular
                           application of EVMS Technology pursuant to Section
                           3.1.

                  3.4      Exercise of Option. GMP shall exercise its option to
                           obtain a license hereunder by delivering to EVMS a
                           written notice within the option period which
                           specifies the particular application of EVMS
                           Technology for which the option is being exercised.
                           GMP and EVMS shall have a period of sixty (60) days
                           from the date of exercise of option by GMP within
                           which to agree upon the initial royalty, royalty rate
                           and commercial development obligations and other
                           terms and conditions of the license satisfactory to
                           both parties.

                  3.5      Reservation of Rights. EVMS reserves the right to use
                           any EVMS Technology that may be subject to an option
                           pursuant to this Agreement or covered by a license
                           granted hereunder solely for EVMS' and/or the
                           contributing subcontractor's own educational and
                           research purposes, without EVMS being obligated to
                           pay GMP any royalties or other compensation related
                           thereto.

                  3.6      Right of First Refusal. In the event GMP does not
                           acquire rights to the EVMS Technology as provided
                           above, and EVMS desires to subsequently license that
                           EVMS Technology to a third party, EVMS shall first
                           offer such a license to GMP on the same terms and
                           conditions as that offered to the third party. If GMP
                           fails to exercise such offer within thirty (30) days
                           following receipt of such an offer, EVMS shall have
                           the right to license such technology to a third party
                           on the same terms and conditions.

                                                                               7
<PAGE>   8

         4.       WARRANTIES.

                  4.1      Warranties. EVMS hereby warrants and represents to
                           GMP that: (i) no third parties have or will have any
                           rights to any EVMS or GMP Technologies; (ii) EVMS has
                           or will have the right to convey or cause to be
                           conveyed to GMP ownership of GMP Technology and
                           indicia of the same as described in Section 5.1
                           hereof; and (iii) it has the full right and power to
                           enter into this Agreement and the entering into and
                           performance under the Agreement shall not constitute
                           a breach of or default under any agreement with any
                           third party.

                  4.2      No Other Warranties. Except as provided in Section
                           4.1 above, EVMS MAKES NO WARRANTIES CONCERNING THE
                           RESEARCH PROGRAM OR ANY EVMS TECHNOLOGY OR EVMS
                           PATENT RIGHTS THAT MAY BE SUBJECT TO THIS AGREEMENT.
                           WITHOUT LIMITING THE FOREGOING, EVMS DOES NOT
                           REPRESENT OR WARRANT THAT IT WILL SUCCESSFULLY
                           COMPLETE THE RESEARCH PROGRAM OR THAT, IF COMPLETED,
                           THE RESEARCH PROGRAM WILL RESULT IN EVMS TECHNOLOGY
                           WHICH WILL BE SUBJECT TO AN OPTION HEREUNDER OR WHICH
                           GMP WILL DESIRE TO LICENSE. EVMS MAKES NO EXPRESS OR
                           IMPLIED WARRANTY, INCLUDING BUT NOT LIMITED TO ANY
                           WARRANTY OF MERCHANTABILITY OR FITNESS FOR A
                           PARTICULAR PURPOSE, AS TO ANY LICENSED PRODUCT. EVMS
                           MAKES NO WARRANTY OR REPRESENTATION AS TO THE
                           VALIDITY OR SCOPE OF ANY EVMS PATENT RIGHTS OR THAT
                           ANY LICENSED PRODUCT WILL BE FREE FROM ANY
                           INFRINGEMENT OF PATENTS OF THIRD PARTIES, OR THAT NO
                           THIRD PARTIES ARE IN ANY WAY INFRINGING EVMS PATENT
                           RIGHTS.

         5.       INTERESTS IN INTELLECTUAL PROPERTY.

                  5.1      Title. EVMS shall retain such ownership and title to
                           EVMS Technology subject to the option of GMP set
                           forth herein. EVMS shall, in the good faith exercise
                           of its discretion, undertake reasonable efforts to
                           preserve and maintain its ownership and title in EVMS
                           Technology. GMP shall own all rights, title and
                           interest in GMP Technology, free and clear of all
                           royalties, liens, claims or other encumbrances or
                           obligations. EVMS agrees, and agrees to cause each
                           EVMS Agent to agree, in writing, to assign or
                           transfer all interest in GMP Technology to GMP and to
                           sign all patent applications and documents evidencing
                           ownership of such technology by GMP without
                           additional costs or payments.

                                                                               8
<PAGE>   9

         6.       CONFIDENTIALITY AND PUBLICATION.

                  6.1      Confidential Information. The parties agree that
                           during the term of and any subsequent extension of
                           this Agreement and for a period of five (5) years
                           after it terminates or for as long as any
                           Confidential Information not otherwise includable
                           within patent rights is being utilized within a
                           Licensed Product, whichever is longer, a party having
                           Confidential Information of another party will not
                           use or intentionally disclose such Confidential
                           Information to any third party without the prior
                           written consent of the party which owns the
                           Confidential Information.

                  6.2      Publications. GMP acknowledges that it is the general
                           policy of EVMS to encourage publication of research
                           results in technical or scientific journals; and
                           subject to EVMS meeting its disclosure obligations
                           under Sections 3.2 and 6.1 hereof, GMP agrees that
                           EVMS shall have a right to publish in accordance with
                           its general policy. Prior to such publication, EVMS
                           shall submit to GMP copies of proposed publications
                           which contain subject matter relating to EVMS or GMP
                           Technology and afford GMP a period of thirty (30)
                           days to review the publication. Upon written request
                           by GMP prior to the expiration of such thirty (30)
                           days period and provided that GMP shall have
                           exercised its option to one or more applications
                           included within the subject matter of such
                           publication, EVMS shall delay any such publication
                           for up to sixty (60) days from the date of such
                           request to allow for the preparation and filing of a
                           patent application.

                  6.3      Publicity. Except as otherwise provided herein or
                           required by law, no party shall originate any
                           publication, news release or other public
                           announcement, written or oral, whether in the public
                           press, or stockholders, reports, or otherwise,
                           relating to this Agreement or to any license granted
                           hereunder, or to the performance thereunder, without
                           the prior written approval of the other party, which
                           approval shall be acted upon within five business
                           days and shall not be unreasonably withheld.

                                                                               9
<PAGE>   10

         7.       TERM AND TERMINATION.

                  7.1      Term. Unless terminated sooner, the initial term of
                           this Agreement shall commence on the date set forth
                           above and shall continue for a period of five (5)
                           years.

                  7.2      Termination Upon Default. Any one or more of the
                           following events shall constitute an event of default
                           hereunder: (i) the failure of a party to pay any
                           amounts when due hereunder and the failure to cure
                           within fifteen (15) days after receipt of notice from
                           the other party specifying in reasonable detail the
                           nature of such default; (ii) the failure of a party
                           to perform any obligation required of it to be
                           performed hereunder, and the failure to cure within
                           sixty (60) days after receipt of notice from the
                           other party specifying in reasonable detail the
                           nature of such default; and (iii) the termination of
                           the License Agreement as a result of a breach or
                           default by the Licensor under the License Agreement.
                           Upon the occurrence of an event of default, the
                           non-defaulting party may deliver to the defaulting
                           party written notice of intent to terminate, such
                           termination to be effective upon the date set forth
                           in such notice. Such termination rights shall be in
                           addition to and not in substitution for any other
                           remedies that may be available to the non-defaulting
                           party serving such notice against the defaulting
                           party. Termination pursuant to this Section 7.2 shall
                           not relieve the defaulting party of liability and
                           damages to non-defaulting party for breach of this
                           Agreement. Waiver by any party of a single default or
                           a succession of defaults shall not deprive such party
                           of any right to terminate this Agreement arising by
                           reason of any subsequent default

                  7.3      Termination on Insolvency. This Agreement may be
                           terminated as to any party ("Insolvent Party") by
                           another party giving written notice of termination to
                           the Insolvent Party upon the filing of bankruptcy or
                           bankruptcy of the Insolvent Party or the appointment
                           of a receiver of any of the Insolvent Party's assets,
                           or the making by the Insolvent Party of any
                           assignment for the benefit of creditors, or the
                           institution of any proceedings against the Insolvent
                           Party under any bankruptcy law. Termination shall be
                           effective upon the date specified in this notice.

                  7.4      Effect of Expiration or Termination.

                           7.4.1    Termination Upon Default of GMP. Upon the
                                    termination of this Agreement by reason of a
                                    default by GMP, neither party shall have any
                                    further rights or obligations with respect
                                    to this Agreement, other than the obligation
                                    of GMP to make any and all final payments
                                    accrued prior to the date of termination and
                                    the obligation of the parties to make all
                                    reports required hereunder. Upon such
                                    termination of this Agreement, the parties
                                    shall continue to abide by their obligations
                                    as described in Articles 5 and 6, and each
                                    party hereto shall fulfill any other
                                    obligations incurred prior to such
                                    termination. Any such termination of this
                                    Agreement

                                                                              10
<PAGE>   11

                                    shall not constitute the termination of any
                                    license or any other agreements between the
                                    parties which are then in effect except as
                                    expressly provided herein.

                           7.4.2    Expiration or Termination Upon Default of
                                    EVMS. Upon the expiration of this Agreement
                                    at its regularly scheduled expiration date,
                                    or upon a termination of this Agreement on
                                    account of a default by EVMS, then EVMS
                                    shall make the disclosures required by
                                    Section 3.2 for EVMS and GMP Technology
                                    conceived or reduced to practice up to the
                                    date of said expiration or termination; and
                                    GMP shall have the right to exercise its
                                    option with respect to said EVMS Technology
                                    in accordance with the schedule and
                                    procedures specified in Sections 3.4 and 3.5
                                    above. Additionally, each party shall
                                    perform all other obligations up to the date
                                    of said expiration or termination; and the
                                    parties shall continue to abide by their
                                    obligations described in Articles 5 and 6;
                                    and any previously existing license
                                    agreements or other agreements between the
                                    parties shall continue in effect.

         8.       ASSIGNMENT: SUCCESSORS

                  8.1      Assignment. This Agreement may not be assigned by GMP
                           without the prior written consent of EVMS except to a
                           successor in interest to all or substantially all of
                           the business assets of GMP, whether by way of a
                           merger, consolidation, sale of all or substantially
                           all of GMP's assets, change of control or similar
                           transaction.

                  8.2      Binding Upon Successors and Assigns. Subject to the
                           limitations on assignment set forth herein, this
                           Agreement shall be binding upon and inure to the
                           benefit of any successors in interest and assigns of
                           EVMS and GMP. Any such successor to or assignee of a
                           party's interest shall expressly assume in writing
                           the performance of all the terms and conditions of
                           this Agreement to be performed by such party.

         9.       GENERAL PROVISIONS.

                  9.1      Independent Contractors. The relationship between
                           EVMS and GMP is that of independent contractors. EVMS
                           and GMP are not joint venturers, partners, principal
                           and agent, master and servant, employer or employee,
                           and have no other relationship other than independent
                           contracting parties. EVMS and GMP shall have no power
                           to bind or obligate each other in any manner, other
                           than as is expressly set forth in this Agreement.

                  9.2      Arbitration. Any controversy or claim arising out of
                           or relating to this Agreement, or the breach thereof,
                           shall be settled by alternative dispute resolution,
                           such as, for example, arbitration or mediation. If
                           the parties cannot agree on a form of alternative
                           dispute resolution then any dispute shall be resolved
                           by binding arbitration in accordance with the

                                                                              11
<PAGE>   12

                           Commercial Arbitration Rules of the American
                           Arbitration Association ("AAA").

                  9.3      Entire Agreement; Modification. This Agreement and
                           other agreements executed by the parties or
                           affiliated entities dated this even date constitute
                           the entire agreement and understanding between the
                           parties as to the subject matter hereof. There shall
                           be no amendments or modifications to this Agreement
                           except by a written document, which is signed by both
                           parties.

                  9.4      Virginia Law. This Agreement shall be construed and
                           enforced in accordance with the laws of the State of
                           Virginia.

                  9.5      Headings. The headings for each article and section
                           in this Agreement have been inserted for the
                           convenience of references only and are not intended
                           to limit or expand on the meaning of the language
                           contained in the particular article or section.

                  9.6      Severability. Should any one or more of the
                           provisions of this Agreement be held invalid or
                           unenforceable by a court of competent jurisdiction,
                           it shall be considered severed from this Agreement
                           and shall not serve to invalidate the remaining
                           provision hereof. The parties shall make a good faith
                           effort to replace any invalid or unenforceable
                           provisions with a valid and enforceable one such that
                           the objectives contemplated by them when entering
                           this Agreement may be realized.

                  9.7      No Waiver. Any delay in enforcing a party's rights
                           under this Agreement or any waiver as to a particular
                           default or other matter shall not constitute a waiver
                           of such party's rights to the future enforcement of
                           its rights under this Agreement, excepting only as to
                           an express written and signed waiver as to a
                           particular matter for a particular period of time.

                  9.8      Attorneys' Fees. In the event of a dispute among the
                           parties hereto or in the event of any default
                           hereunder, the party prevailing in the resolution of
                           any such dispute or default shall be entitled to
                           recover its reasonable attorneys' fees and other
                           costs incurred in connection with resolving such
                           dispute or default.

                  9.9      Notices. Any notices required by this Agreement shall
                           be in writing, shall specifically refer to this
                           Agreement and shall be sent by registered or
                           certified airmail, postage prepaid, or by facsimile,
                           telex or cable, charges prepaid, or by overnight
                           courier, postage prepaid, and shall be forwarded to
                           the respective addresses set forth below unless
                           subsequently changed by written notice to the other
                           party:

                                                                              12
<PAGE>   13

                  FOR EVMS: Medical College of Hampton Roads
                            d/b/a Eastern VirginiaMedical School
                            P.O. Box 1980
                            Norfolk, Virginia 23501
                            Attn:  Vice President for Finance and Administration
                            Fax No.: (757) 446-6095

                  FOR GMP:  GMP EndoTherapeutics, Inc.
                            One East Broward Blvd., Suite 1701
                            Fort Lauderdale, Florida  33301
                            Attn: Dr. Bart Chernow
                            Fax No.: (954) 745-3511

                  Notice shall be deemed delivered upon the earlier of (i) when
                  received, (ii) three (3) days after deposit into the mail,
                  (iii) the date notice is sent via telefax, telex or cable, or
                  (iv) the day immediately following delivery to overnight
                  courier (except Sunday and holidays).

                  9.10     Compliance with U.S. Laws. Nothing contained in this
                           Agreement shall require or permit EVMS or GMP to do
                           any act inconsistent with the requirements of any
                           United States law, regulation or executive order as
                           the same may be in effect from time to time.

                  9.11     Third Party Compliance. In the event and to the
                           extent EVMS engages other persons or entities not a
                           party to this Agreement to conduct all or any part of
                           the work to be performed under this Agreement, it
                           shall require such persons or entities to enter into
                           written agreements which contractually obligate such
                           persons or entities to the same requirements imposed
                           upon EVMS hereunder, including, without limitation,
                           the obligations under Articles 3, 4, 5 and 6 hereof.
                           EVMS shall provide GMP with copies of such written
                           agreements.

                  9.12     Estoppel Certificates. EVMS shall, from time to time,
                           upon written request of GMP, any of its Affiliates or
                           transferees or potential transferees, issue an
                           estoppel certificate to the requesting entity setting
                           forth the status of this Agreement, and, if in
                           default, stipulating the actions necessary to cure
                           such default.

                  9.13     Counterparts. This Unanimous Written Consent may be
                           signed in one or more counterparts, each of which
                           shall be deemed an original, but of which together
                           shall constitute one instrument.

                                                                              13
<PAGE>   14

         IN WITNESS WHEREOF, the parties have executed this Agreement by their
duly authorized representatives as of the date set forth above.

MEDICAL COLLEGE OF HAMPTON ROADS d/b/a EASTERN VIRGINIA MEDICAL SCHOOL GMP
ENDOTHERAPEUTICS, INC.

By:                                          By:
   ----------------------------------            ------------------------------
     David Thiel, Vice President for              Bart Chernow, M.D., President
     Administration and Finance

By:
   ----------------------------------
     Dr. Aaron Vinick

                                                                              14<PAGE>   1

                                                                    EXHIBIT 10.6

                           PATENT AND KNOW-HOW LICENSE
                                N(DEGREE) L99102

BY AND BETWEEN

The CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE, a French scientific and
technological public establishment, having a registered office at 3 rue
Michel-Ange - 75794 PARIS Cedex 16 - France represented by its General Manager,
Mrs. Catherine BRECHIGNAC, hereinafter referred to as "CNRS"

                                    ON ONE HAND

AND

GLOBAL OXYCELL INC., a US limited liability company whose registered office is
One East Broward Blvd, Suite 1701, Fort Lauderdale, Florida 33301 - USA
represented by its Chief Executive Officer, Dr. Bart CHERNOW, hereinafter
referred to as "OXYCELL"

                                    ON THE OTHER HAND

The CNRS and OXYCELL are hereinafter jointly referred to as "PARTIES".

<PAGE>   2

WHEREAS:

The LABORATORY and in particular, the group directed by Mr. Jean-Marie LEHN has
been working for many years on the biological applications of supramolecular
chemistry.

Certain research performed in this LABORATORY and concerning the design and
evaluation of artificial vectors for gene transfer, has resulted in the filing
of the international PCT application on February 28, 1997, N(degree) PCT/ FR 97
00364 under priority of two French patent application N(degree) 96.02604 and
N(degree) 96.09557, in the name of the CNRS.

Moreover a US patent application N(degree) US/60-150,574 has been filed on
August 26, 1999 entitled "Enhanced oxygen delivery in mammals, methods and
reagents related thereto", in the name of OXYCELL and naming as inventors Mr.
Claude Nicolau and Mr. Jean-Marie LEHN.

OXYCELL has expressed an interest in obtaining an exclusive and worldwide patent
and know-how license from the CNRS for the research work mentioned herein in
certain therapeutic fields.

NOW, THEREFORE THE PARTIES AGREE AS FOLLOWS:

Preliminary Article - DEFINITIONS

         AFFILIATES shall mean any legal entity which, at the time in question:

         -        directly or indirectly controls OXYCELL; or
         -        is under the same direct or indirect control as OXYCELL; or
         -        is directly or indirectly controlled by OXYCELL.

         A legal entity is considered as controlling another:

         -        when it directly or indirectly owns over 50% (fifty percent)
                  of the capital of this legal entity or more than 50% (fifty
                  percent) of the voting rights of its shareholders or
                  associates; or
         -        when it has the direct or indirect de facto, directly or
                  indirectly, the power to decide within this legal entity how
                  the affairs shall be conducted.

         CONTRACT FIELD shall mean the field of therapeutic, prophylactic
         products for oxygen delivery into human and animal cells, including but
         not limited to improvements in oxygen delivery following disease
         impacted occurrences such as heart stroke and peripheral vascular
         diseases, diabetes, and sickle cell anemia.

         CONTRACT KNOW-HOW, shall mean all the scientific, technical or any
         other knowledge in relation to the implementation of the invention
         protected by the CONTRACT PATENTS and acquired by the LABORATORY during
         its research until the EFFECTIVE DATE.

                                      -2-
<PAGE>   3

         CONTRACT PATENTS shall mean the PCT patent application N(degree)
         PCT/FR/97/00364 filed on February 28, 1997 entitled "Composes
         apparentes a la famille des amidiniums. Compositions pharmaceutiques
         les contenant et leurs applications", in the name of CNRS and naming as
         inventors Jean-Marie LEHN, Pierre LEHN and Jean-Pierre VIGNERON, filed
         under priority of the French patent application filed on March 1, 1996,
         in the name of CNRS, N(degree) 96.02604, entitled "Composes apparentes
         a la famille des amidiniums. Compositions pharmaceutiques les contenant
         et leurs applications", and of the French patent application filed on
         July 30, 1996, in the name of CNRS, N (degree) 96.09557, entitled
         "Composes apparentes a la famille des amidiniums. Compositions
         pharmaceutiques les contenant et leurs applications", as well as all
         issued patents, in part or in full, whether based upon or claiming
         priority to the above application and all rights resulting therefrom
         including without limitation (i) any and all European and foreign
         patent applications and patents resulting from the above-mentioned
         French patent applications, which shall be listed under Exhibit A (ii)
         the patents proceeding from such applications, and (iii) all
         continuations, divisions, continuations-in-part, reissues,
         re-examinations, and extensions thereof.

         CONTRACT PRODUCTS, shall mean any products which (i) are covered by a
         VALID CLAIM of CONTRACT PATENTS and/or the US PATENT in the
         jurisdiction where the products are developed, manufactured and/or sold
         (referred to hereafter as PATENTED CONTRACT PRODUCTS), (ii) would be
         covered by a VALID CLAIM of CONTRACT PATENTS in countries not listed in
         Exhibit A, had such CONTRACT PATENTS been filed in the jurisdiction
         where the products are manufactured and sold and are developed on the
         basis of the CONTRACT KNOW-HOW (referred to hereafter as KNOW-HOW
         CONTRACT PRODUCTS). It is understood by the PARTIES the products which
         would fall under the definition of CONTRACT PRODUCTS in the countries
         where no CONTRACT PATENTS has been filed are necessarily the same
         products that those covered by a VALID CLAIM of CONTRACT PATENTS in
         countries where CONTRACT PATENTS are granted.

         CONTRACT TERRITORY shall mean the entire world.

         EFFECTIVE COMPETITION shall mean a situation in which one or more third
         parties, in a country of the CONTRACT TERRITORY, is marketing a product
         using the same chemical entity, which competes with a CONTRACT PRODUCT
         in the CONTRACT FIELD and the third party's product's sales for a
         calendar quarter are at least 15% (fifteen percent) of the total sales
         of such CONTRACT PRODUCT in such country expressed in equivalent units.
         The third party sales determination in any calendar quarter is
         conclusively deemed to be at least 15% (fifteen percent) of the total
         sales of all CONTRACT PRODUCTS in such country, if a market research
         organization such as IMS has made such determination based on its
         conduct of a market share study, in such country, during such quarter.
         Once a determination is made that EFFECTIVE COMPETITION exists for a
         CONTRACT PRODUCT in any country, such determination shall be made again
         each calendar quarter for so long as such CONTRACT PRODUCT is marketed
         in that country. It is understood by the PARTIES that EFFECTIVE
         COMPETITION shall only apply in countries where no CONTRACT PATENTS
         have been granted.

                                      -3-
<PAGE>   4

         EFFECTIVE DATE, shall mean the last date of signature of the present
         Agreement by the PARTIES.

         LABORATORY shall mean the Unite Propre de Recherche CNRS n(degree) 285,
         "Chimie des Interactions Moleculaires", which is (i) part of the CNRS
         and (ii) legally represented by the CNRS.

         NET SALES, shall mean the gross amount received by OXYCELL and its
         AFFILIATES from their customers including distributors but excluding
         SUBLICENSEES, for sales of CONTRACT PRODUCTS, less any normal trade
         discounts and credit notes and refunds issued in respect of returned
         CONTRACT PRODUCTS, purchase, sales, import, or value added taxes and
         charges in respect to carriage, freight and delivery costs, discounts
         or rebates accrued, incurred or paid to Federal Medicaid or State
         Medicare or other payors and amounts exactly repaid or credited by
         reason of rejections or the return of Contract Products (due to
         recalls, dating or other reasons).

         Should OXYCELL sell CONTRACT PRODUCTS to an AFFILIATE (or vice-versa)
         which thereafter sell them to an unrelated third party, the sales
         between the AFFILIATE (or OXYCELL) and the unrelated third party (and
         not the sales between OXYCELL and its AFFILIATE) shall be considered
         NET SALES.

         In the event that a CONTRACT PRODUCT is sold as part of a combination
         product, the NET SALES of the CONTRACT PRODUCT, for the purposes of
         determining royalty payments, shall be determined by multiplying the
         Net Sales (as defined in this Section) of the combination product by
         the fraction, A/(A+B) where A is the average sale price of the CONTRACT
         PRODUCT when sold separately in finished form and B is the average sale
         price of the other active compound(s) sold separately in finished form.
         In the event that such average sale price cannot be determined for both
         the CONTRACT PRODUCT and other active compound(s) in combination, NET
         SALES for purposes of determining royalty payments shall be calculated
         by multiplying the net sales of the combination products by the
         fraction C/(C+D) where C is OXYCELL's cost of goods of the CONTRACT
         PRODUCT and D is OXYCELL's cost of goods of the other active
         compound(s), determined in accordance with the method of accounting
         normally employed by OXYCELL in computing cost of goods.

         SUBLICENSEES, shall mean any third parties who may obtain a sublicense
         from OXYCELL to develop and/or commercially exploit the CONTRACT
         PRODUCTS in the CONTRACT FIELD.

                                      -4-
<PAGE>   5

         SUBLICENSE REVENUES, shall mean consideration of any kind received by
         Oxycell or its AffiliateS, from their sublicenseeS for sales of
         Contract Products, or for fees received, such as upfront fees or
         milestone fees paid to Oxycell or an Affiliate in consideration for
         such sublicense. However, not included in Sublicense Revenues are
         amounts paid to Oxycell or an Affiliate by the sublicenseeS for product
         development, research work, clinical studies and regulatory approvals
         performed by or for the Oxycell or an Affiliate or third parties on
         their behalf.

         US PATENT, shall mean the US patent Application which has been filed
         under n(degree) US/60-150,574 on August 26, 1999 entitled "Enhanced
         oxygen delivery in mammals, methods and reagents related thereto" as
         well as on any extensions in part or in full of the above application
         and all rights resulting therefrom including but not only (i) any and
         all European and non-US patent applications and patents based upon,
         claiming priority to and/or resulting from the above mentioned US
         PATENT application, (ii) the patents proceedings from such
         applications, (iii) any US utility applications and (iv) all
         continuations divisions, continuations-in-part, reissues,
         reexaminations, and extensions thereof.

         VALID CLAIM shall mean any claim of an issued and unexpired patent or a
         claim of a pending patent application within the CONTRACT PATENTS, or
         the US PATENT which has not been held unpatentable, invalid or
         unenforceable by a court or other government agency of competent
         jurisdiction and has not been admitted to be invalid or unenforceable
         through reissue, re-examination, disclaimer or otherwise; provided,
         however, that if the holding of such court or agency is later reversed
         by a court or agency with overriding authority, the claim shall be
         reinstated as a VALID CLAIM after the date of such reversal.

All plurals may be read in the singular and vice versa.

Article 1 - OBJECT NATURE AND SCOPE

1.1      The CNRS hereby grant OXYCELL which accepts, subject to the terms and
         conditions of the present Agreement, an exclusive license under the
         CONTRACT PATENTS and CONTRACT KNOW-HOW to make, have made, sell, use,
         import, market, offer for sale, have sold and otherwise commercially
         exploit the CONTRACT PRODUCTS in the CONTRACT FIELD and the CONTRACT
         TERRITORY.

1.2      The right to license granted to OXYCELL by the CNRS includes the right
         to grant sublicenses.

1.3      By virtue of the present Agreement, OXYCELL (with respect to the
         sublicensees' rights) will have the sole right to make, have made,
         sell, use, import, market, offer for sale, have sold and otherwise
         commercially exploit the CONTRACT PRODUCTS in the CONTRACT FIELD and
         the CONTRACT TERRITORY.

                                      -5-
<PAGE>   6

Article 2 - RENUNCIATION

         CNRS hereby confirms that it waives all rights whatsoever, as of the
         EFFECTIVE DATE, in the US PATENT in consideration of the payment of the
         financial conditions in accordance with Article 6 of the present
         Agreement.

         Consequently, CNRS irrevocably and expressly waives any claim, law
         suit, proceedings or other action which may have as purpose, reason or
         consequence the ownership of, or the quiet and useful possession and
         enjoyment of the US PATENT by OXYCELL or any other third party claiming
         by or through OXYCELL.

         The present Article shall remain in effect regardless of the expiration
         or termination of the present Agreement.

Article 3 - TERM

         Subject to the provisions of Article 2, the present Agreement shall
         take effect at the EFFECTIVE DATE and unless earlier terminated in
         accordance with the terms herein shall remain in effect on a country by
         country basis for each country:

         (a)      In which VALID CLAIM exists, for the duration of the last
                  VALID CLAIM or for the duration of any extensions by a
                  Supplementary Protection Certificate or an equivalent
                  document.

         (b)      In which no VALID CLAIM exists, or no longer exists, for 10
                  (ten) years as of the date of the first commercialized
                  KNOW-HOW CONTRACT PRODUCT in such country.

         It is expressly agreed that at the expiration of the term of the
         present Agreement, OXYCELL shall have the continuing right to make,
         have made, sell, use, import, market, offer for sale, have sold and
         otherwise commercially exploit the CONTRACT PRODUCTS in the CONTRACT
         FIELD and the CONTRACT TERRITORY without any further royalties.

Article 4 - SUBLICENSES

         4.1      Pursuant to Article 1.2 herein, OXYCELL may grant sublicenses
                  to its AFFILIATES subject to providing prior written
                  notification to the CNRS of the identity of such Affiliate for
                  information purposes only.

                                      -6-
<PAGE>   7
*** CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES
    AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

         OXYCELL may also grant sublicenses to non Affiliates subject to prior
         written approval from the CNRS of the name of any proposed SUBLICENSEE.
         Such prior written approval may not be unreasonably withheld or
         delayed. In the event OXYCELL desires to grant a sublicense to a non
         AFFILIATE, it shall have the right to submit the form of the proposed
         sublicense agreement to CNRS and within 30 (thirty) business days of
         the receipt of that form CNRS shall issue a letter to OXYCELL stating
         that the proposed agreement is in compliance with this Article 4 or, if
         not, stating the changes required to make it compliant. If no such
         response is received within such time period from CNRS, its approval
         shall be deemed to have been given both as to the transaction and form
         of sublicense.

         It is expressly agreed by the PARTIES, that the Sublicense Agreement
         may not contain any exchange in kind provision pursuant to which the
         SUBLICENSEE will pay OXYCELL with its own products.

4.2      OXYCELL agrees, subject to the SUBLICENSEES approval, to include within
         the terms of any sublicenses a clause which permits the CNRS to audit
         the AFFILIATES and SUBLICENSEES accounts related to the present
         Agreement.

4.3      OXYCELL shall include within the terms of any sublicense obligations of
         confidentiality which are similar to those set out in Article 9 below.

Article 5 - TRANSFER

         The present Agreement is granted intuitu personae. It is therefore
         personal, non- transferable and non-assignable, except to an AFFILIATE,
         without the prior written consent of the CNRS which shall not be
         unreasonably withheld or delayed.

         It is hereby understood that any company to which OXYCELL's rights and
         obligations are assigned, shall be subject to the same obligations as
         those of OXYCELL herein, unless the new contracting parties should
         reach another mutual agreement.

Article 6 - FINANCIAL CONDITIONS

6.1      The present license is granted in exchange for payment by OXYCELL to
         the CNRS of:

         a)       A lump sum payment of ([***] excluding tax) due upon the
                  EFFECTIVE DATE.

                                      -7-
<PAGE>   8
*** CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES
    AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

         b)       A lump sum payment of ([***] excluding tax) due at each
                  anniversary date of the EFFECTIVE DATE, until the CONTRACT
                  PATENTS have been granted or until the payment of either of
                  the lump sums specified under Article 6.1 c) and 6.1 d) have
                  been made, whichever occurs first, and in any event, when the
                  lump sum payment specified under Article 6.1.e) has been paid.

         c)       A lump sum payment of ([***] excluding tax) due when the
                  European patent of the CONTRACT PATENTS is granted.

         d)       A lump sum payment of ([***] excluding tax) due when the first
                  US patent of the CONTRACT PATENTS is granted.

         e)       A lump sum payment of ([***] excluding tax) once OXYCELL has
                  obtained the FDA approval for the commercial use of the
                  CONTRACT PRODUCTS in humans. One third of the above [***] lump
                  sum shall be however paid in advance should OXYCELL obtain the
                  FDA approval for the commercial use of the CONTRACT PRODUCTS
                  in animals. The advance payment shall be made at the date of
                  such approval.

                  OXYCELL shall inform the CNRS in writing of the dates of each
                  event described herein, within two months after it occurs.

         f)       Royalty payments of (i) [***] of NET SALES of the PATENTED
                  CONTRACT PRODUCTS (other than those based on the US PATENT)
                  covered by a VALID CLAIM of the CONTRACT PATENTS or (ii) [***]
                  of NET SALES of the PATENTED CONTRACT PRODUCTS covered by a
                  VALID CLAIM of the US PATENT and/or KNOW-HOW CONTRACT
                  PRODUCTS, received by OXYCELL and/or its AFFILIATES.

                  For the avoidance of doubt, the royalty rate of [***] as set
                  out in (ii) is applicable only if there is no VALID CLAIM of
                  CONTRACT PATENTS (other than those based on the US PATENT)
                  covering the PATENTED CONTRACT PRODUCTS.

         g)       A percentage of sublicense revenues received by OXYCELL or an
                  affiliate, as calculate hereunder depending on the date of
                  execution of the relevant sublicense contracts:

                                      -8-
<PAGE>   9
*** CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES
    AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

                  -        [***] of the above SUBLICENSE REVENUES for PATENTED
                           CONTRACT PRODUCTS (other than those based on the US
                           PATENT) covered by a VALID CLAIM of the CONTRACT
                           PATENTS or [***] of the above SUBLICENSE REVENUES for
                           the PATENTED CONTRACT PRODUCTS covered by a VALID
                           CLAIM of the US PATENT and/or KNOW-HOW CONTRACT
                           PRODUCTS, for payment received pursuant a sublicense
                           contract executed before the experimentation on the
                           first patient; or

                  -        [***] of the above SUBLICENSE REVENUES for PATENTED
                           CONTRACT PRODUCTS (other than those based on the US
                           PATENT) covered by a VALID CLAIM of the CONTRACT
                           PATENTS or [***] of the above SUBLICENSE REVENUES for
                           PATENTED CONTRACT PRODUCTS covered by a VALID CLAIM
                           of the US PATENT and/or KNOW-HOW CONTRACT PRODUCTS,
                           for payment received pursuant a sublicense contract
                           executed after the experimentation on the first
                           patient but before the first FDA approval for the
                           commercial use of the CONTRACT PRODUCTS; or

                  -        [***] of the above SUBLICENSE REVENUES for PATENTED
                           CONTRACT PRODUCTS (other than those based on the US
                           PATENT) covered by a VALID CLAIM of the CONTRACT
                           PATENTS or [***] of the above SUBLICENSE REVENUES for
                           PATENTED CONTRACT PRODUCTS covered by a VALID CLAIM
                           of the US PATENT and/or KNOW-HOW CONTRACT PRODUCTS,
                           for payment received pursuant a sublicense contract
                           executed after the first FDA approval for the
                           commercial use of the CONTRACT PRODUCTS.

         h)       No royalties or sublicenses fees shall be payable on Contract
                  PRODUCT sales between OXYCELL and any AFFILIATE, in which
                  event the royalty or sublicenses fees shall be based upon the
                  NET SALES of the AFFILIATE.

         i)       No multiple royalties or sublicenses fees shall be due and
                  payable because any CONTRACT PRODUCT are covered by more than
                  one patent which is within the definition of ContracT PATENTS.

                  In the event OXYCELL, any AFFILIATE, or any sublicensee does
                  not have freedom to operate and therefore is obliged to pay an
                  additional amount to third parties on Contract PRODUCTS,
                  (other than payments to ULP pursuant to a sponsored research
                  agreement executed by OXYCELL and ULP) in order to make, have
                  made, sell, use, import, market, offer for sale, have sold and
                  otherwise commercially exploit such CONTRACT PRODUCT, the
                  royalties due to CNRS hereunder shall be reduced by 50% (fifty
                  percent) of the amount due to said third parties but in no
                  event shall the effective royalty rate due CNRS be less than
                  one-half of the stated amount due as provided in paragraph
                  6.1(f) and (g) above.

                                      -9-
<PAGE>   10

         j)       CNRS agrees that no royalties or sublicenses fees shall be due
                  for the internal use of the Contract PRODUCTS for research and
                  commercial development purposes by Oxycell and AFFILIATES or
                  for use by third parties providing research and development
                  activities on behalf of OXYCELL or AFFILIATES in seeking
                  governmental and professional approvals, certifications or
                  endorsements, or for training purposes, except where Oxycell
                  or any AFFILIATES receives revenues for the sale of the
                  CONTRACT PRODUCTS to the organization using the device for
                  such stated proposes.

6.2      If OXYCELL justifies the existence of EFFECTIVE COMPETITION in any of
         the countries of the CONTRACT TERRITORY in which there is no VALID
         CLAIM, the PARTIES shall meet and negotiate in good faith new financial
         conditions, for said countries, to be mutually agreed by the PARTIES.

6.3      The NET SALES and Sublicense Revenues used for computing the royalties
         or sublicenses fees payable to CNRS thereunder shall be computed, and
         royalties or sublicenses fees shall be paid in US dollars.

Article 7 - RECORD KEEPING AND AUDIT RIGHTS

7.1      OXYCELL shall keep accounts which shall include all the elements
         necessary to precisely calculate the NET SALES and Sublicense Revenues.

7.2      No later than January 31st of every year, OXYCELL shall provide the
         CNRS with a sale report setting out NET SALES and Sublicense Revenues
         by country for the year ending on the previous December 31st.

7.3      Should there be no sale or sublicense revenues, OXYCELL shall
         nevertheless send the CNRS a sales report in the month of January of
         each year stating the absence of any sales during the year under
         consideration and indicating the cause for this lack of sales or
         SUBLICENSE REVENUES and the difficulties encountered.

7.4      All sales reports shall be sent to the Service Financier de la
         Delegation du Siege du CNRS, 3 rue Michel-Ange - 75794 PARIS Cedex 16.
         Said reports shall include the number of the present agreement.

7.5      The amounts due by OXYCELL to the CNRS must be paid within 35
         (thirty-five) days following issuance of an invoice by CNRS to the
         person and bank address indicated in Article 7.6 below.

7.6      Payments shall be made to the CNRS by check to the order l'Agent
         Comptable Secondaire du CNRS, Delegation Paris Michel Ange, Paierie
         Generale PARIS - Code Banque 30091 - Code Guichet N(degree) 75200 -
         Compte N(degree) 20003000505 - Cle 69.

                                      -10-
<PAGE>   11

         Checks shall be addressed to the attention of: Agent Comptable
         Principal du CNRS - 3 rue Michel-Ange - 75794 PARIS Cedex 16.

7.7      Any sums which remain unpaid by OXYCELL to the CNRS within the periods
         set out hereunder shall be subject to interest at the rate determined
         according to the rules applicable to the French Public Establishments
         (prevailing legal interest rate + 2 points), without prejudice to the
         right of CNRS to initiate termination proceedings pursuant to Article
         13 below.

7.8      No more frequently than once every calendar year, OXYCELL shall permit
         an expert accountant hired by the CNRS to inspect the records and
         invoices of OXYCELL during normal working hours and upon providing
         reasonable notice, and shall permit said accountant to take copies and
         extracts for the sole purpose of verification of the reports sent to
         the CNRS hereunder. The CNRS shall keep secret and shall procure its
         expert accountant to keep secret any information relating to the
         activities of OXYCELL or any AFFILIATE obtained pursuant to such
         inspections. The expense of all such inspections shall be for the CNRS,
         except in the case of back royalties of 5% (five percent) being due by
         OXYCELL as a result of said audit.

Article 8 - EXPLOITATION

8.1      OXYCELL agrees to exploit the present license and to make its best
         efforts in a commercially reasonable manner to develop, make, have
         made, sell, use, and otherwise commercially exploit the CONTRACT
         PRODUCTS.

8.2      OXYCELL agrees to provide annual reports describing the development and
         exploitation of the CONTRACT PRODUCTS. If on the basis of such annual
         report it appears that OXYCELL has not pursued the development of the
         CONTRACT PRODUCTS, the CNRS may notify OXYCELL and request for further
         information within 30 days of the reception of the annual report.
         OXYCELL shall within 60 days of such notification inform CNRS of its
         intention to pursue the development of CONTRACT PRODUCTS. Should
         OXYCELL decide not to develop the CONTRACT PRODUCTS, CNRS may terminate
         the Agreement pursuant to Article 13.2 below.

8.3      Except as provided in Article 9.5 below OXYCELL, its subsidiaries,
         AFFILIATES, or SUBLICENSEES agree not to use the names "Centre National
         de la Recherche Scientifique" or "CNRS" or any trademark, distinctive
         sign or adaptations thereof which belongs to the CNRS or the names of
         the CNRS inventors, for commercial purposes, without receiving prior
         written approval from the CNRS or the natural person concerned, as the
         case may be. Consent from CNRS will be promptly considered and not be
         unreasonably withheld.

                                      -11-
<PAGE>   12

8.4      OXYCELL, its subsidiaries, AFFILIATES, or SUBLICENSEES shall
         commercialize the CONTRACT PRODUCTS under their own trademarks or under
         trademarks for which they have obtained a license. The CNRS shall have
         no rights to such trademarks. All administrative authorizations
         obtained by OXYCELL for the purpose of manufacturing and/or
         commercializing the CONTRACT PRODUCTS shall be obtained for OXYCELL or
         for any party which it shall have designated and subject to Article 8.6
         hereunder, the CNRS shall claim no rights thereto.

8.5      CNRS shall do its best reasonable efforts to assist OXYCELL, directly
         or through the LABORATORY in obtaining any administrative
         authorizations which may be required for the purpose of manufacturing
         and/or commercializing the CONTRACT PRODUCTS.

8.6      Without prejudice to the terms of Article 10.4 hereunder, OXYCELL
         agrees to provide the CNRS with a copy of all administrative
         authorizations, notably any official marketing approval that it obtains
         for the purpose of manufacturing and/or commercializing the CONTRACT
         PRODUCTS no later than 3 (three) months after obtaining such final
         authorizations.

8.7      OXYCELL has a general knowledge in respect of (i) the CONTRACT FIELD
         and (ii) developing, making, selling, using, and otherwise commercially
         exploiting the CONTRACT PRODUCT should such exploitation be reasonably
         possible.

Article 9 - CONFIDENTIALITY

9.1      Each PARTY agrees to respect and keep strictly confidential all
         scientific and technical information belonging to the other PARTY and
         any other information of any nature belonging to the other PARTY about
         which they may have knowledge due the negotiations and execution of the
         present Agreement.

         The PARTIES shall not use such information for any other purpose than
         the performance of the present Agreement and shall only disclose this
         information its employees on a strict need-to-know basis.

9.2      The PARTIES shall assure that their personnel and others in their
         service are bound by the same obligations of confidentiality described
         hereunder. Moreover, OXYCELL shall include confidentiality obligations
         no less onerous than the present Article 9 in any sublicenses it may
         grant to SUBLICENSEES.

9.3      The confidentiality obligations between the PARTIES in the present
         Article 9 shall not include the use or disclosure of confidential
         information that the receiving PARTY can show:

         a)       Was disclosed by the mutual agreement of the PARTIES, or was
                  disclosed by the owning PARTY; or

                                      -12-
<PAGE>   13

         b)       Was in the public domain at the moment of disclosure or
                  entered the public domain through no act or fault of the
                  receiving PARTY; or

         c)       Was made available as a matter of lawful right by a third
                  PARTY without breach of any of the confidentiality obligations
                  herein; or

         d)       Was in the possession of the receiving PARTY at the time of
                  disclosure by the owning PARTY; or

         e)       Was disclosed by lawful right, to remain in compliance with a
                  legal or regulatory imperative, an arbitration settlement or a
                  final legal decision; or

         f)       Was disclosed after obtaining the prior authorization of the
                  owning PARTY; or

         g)       Was independently developed by or on behalf of the receiving
                  PARTY without use of any confidential information received
                  from the owning PARTY; or

         h)       Was disclosed in the course of exercising its rights to
                  validly exploit VALID CLAIMS including its rights to defend
                  such exploitation against third parties.

9.4      The present Article 9 shall remain in effect until the expiration of
         the last of the CONTRACT PATENTS, the expiration or termination of the
         present Agreement notwithstanding.

9.5      OXYCELL shall have the right to use and disclose the names of CNRS and
         the inventors and other information otherwise restricted in use and
         disclosure under the present Agreement to the extent necessary to
         comply with applicable governmental orders and governing laws and
         regulations.

Article 10 - INTELLECTUAL PROPERTY

10.1     Any and all decisions concerning the prosecution and maintenance of the
         intellectual property necessary to the validity of the CONTRACT PATENTS
         in the Contract territory shall belong exclusively to the CNRS which
         shall be responsible for the prosecution and maintenance fees of said
         CONTRACT PATENTS. CNRS shall provide copies of the main relevant
         prosecution and maintenance documents to OXYCELL, and keep OXYCELL
         informed of the status of the CONTRACT PATENTS at OXYCELL formal
         request.

                                      -13-
<PAGE>   14

10.2     Should the CNRS wish to either not initiate or abandon the prosecution
         or maintenance of the CONTRACT PATENTS in any country within the
         CONTRACT TERRITORY, it shall notify OXYCELL 2 (two) months prior to the
         next deadline for filing the necessary documents or making the
         necessary payment of maintenance fees of said patent applications or
         patent(s). OXYCELL may take over the prosecution and maintenance of
         said CONTRACT PATENTS subject to notifying the CNRS no later than 1
         (one) month prior to such deadline. In this case the terms of the
         present Agreement shall remain in effect and OXYCELL shall be
         responsible for the prosecution and maintenance fees for said CONTRACT
         PATENTS and no royalties shall be due to the CNRS in any such country
         as long as OXYCELL shall continue to support the prosecution or
         maintenance of the CONTRACT PATENTS.

Article 11 - INFRINGEMENT

11.1     The PARTIES shall inform each other within the shortest possible delay
         of any third party infringement of which they may become aware and/or
         of any infringement claims or actions, which may be taken against it.

11.2     The CNRS may take action at its own expense against any third party
         infringement to the CONTRACT PATENTS, with the understanding that any
         indemnification awarded by court decision as a result of said action
         shall irrevocably and entirely be the property of the CNRS. Moreover
         CNRS shall inform any other beneficiary of a license in respect of the
         CONTRACT PATENTS in order to organize any possible common action
         against any third party infringement.

         This shall not prevent OXYCELL from taking action against third party
         infringement at its own expense to obtain indemnification for damages
         which it alone has incurred and any indemnification awarded by court
         decision from said action shall be irrevocably and entirely the
         property of OXYCELL.

11.3     Subject to Article 11.2 OXYCELL shall have right to enforce any VALID
         CLAIMS within the CONTRACT FIELD against any infringement or alleged
         infringement thereof, and shall at all times keep CNRS informed as to
         the status thereof. OXYCELL may, in its sole judgment and at its own
         expense, institute suit against any such infringer or alleged infringer
         and control, settle, and defend such suit in a manner consistent with
         the terms and provisions hereof and recover, for its account, any
         damages, awards or settlements resulting therefrom, subject to Article
         11.4. This right to sue for infringement shall not be used in an
         arbitrary or capricious manner. CNRS shall reasonably cooperate in any
         such litigation at OXYCELL's expense.

                                      -14-
<PAGE>   15

11.4     Any recovery by OXYCELL under Articles 11.2 and 11.3 shall be deemed to
         reflect loss of commercial sales, and OXYCELL shall pay to CNRS the
         same percent of the recovery net of all reasonable costs and expenses
         associated with each suit or settlement as if such net constituted
         SUBLICENSE REVENUES. If the cost and expenses exceed the recovery, then
         one-half (1/2) of the excess shall be credited against royalties
         payable by OXYCELL to CNRS hereunder in connection with sales or
         services in the country of such legal proceedings, provided, however,
         that any such credit under the present Article 11.4 shall not exceed
         fifty percent (50%) of the royalties otherwise payable to CNRS with
         regard to sales or services in the country of such action in any one
         calendar year, with any excess credit being carried forward to future
         calendar years.

11.5     Should OXYCELL, or its AFFILIATES, become the object of infringement
         claims as a result of the commercialization of the CONTRACT PRODUCTS
         which have been identified or developed by the use of the CONTRACT
         PATENTS and the CONTRACT KNOW HOW, the CNRS shall provide OXYCELL with
         any documents or information which it may have in its possession which
         may be necessary to assist in the defense of OXYCELL or its AFFILIATES.

11.6     The present article shall not in any way be considered to constitute a
         waiver by the CNRS to take any action or intervention.

Article 12 - WARRANTIES

12.1     CNRS declares and warrants that it is the sole owner of the CONTRACT
         PATENTS.

12.2     CNRS declares and warrants that the CONTRACT PATENTS with respect to
         the CONTRACT FIELD are not subject to any pledge, security, license,
         authorization to use, right of preference, rights of first refusal or
         right of preemption nor more generally to any right or restriction or
         covenant in whatever form in any country on behalf or in favor of any
         third party which might affect the quiet and useful possession and
         enjoyment of the CONTRACT PATENTS by OXYCELL.

12.3     Subject to Article 12.2 OXYCELL shall not call on the CNRS in guarantee
         for any damages or prejudice of any nature caused by the CONTRACT
         PRODUCTS. OXYCELL is solely responsible to its clients and/or any third
         parties for the quality and performance of the CONTRACT PRODUCTS.

                                      -15-
<PAGE>   16

Article 13 - TERMINATION

13.1     Should OXYCELL cease business operations or be the object of a
         liquidation procedure, the CNRS may terminate the present Agreement if
         it so wishes subject to notifying OXYCELL. After 1 (one) month without
         a response to this notification by Oxycell, the judicial administrator
         or liquidator as the case may be, and subject to the applicable and
         legal regulations in the United States, the present Agreement shall be
         immediately terminated by right.

13.2     The present Agreement may be terminated as of right, without any
         judicial formalities, by either of the PARTIES in the event that the
         other PARTY fails to perform one or more of the material obligations
         contained in the various clauses of the present Agreement, including
         Article 6. This termination shall only become effective 3 (three)
         months after the complaining PARTY sends a notice exposing the motives
         of the complaint and then only if the PARTY at fault has not, within
         this period, fulfilled its obligations or shown proof of a case of
         force majeure that prevented it from fulfilling its obligations. The
         exercise of such right to termination does not exempt the PARTY in
         default from fulfilling the obligations accrued prior to the date of
         termination.

13.3     Subject to the obtaining by OXYCELL of the administrative
         authorizations to use the CONTRACTS PRODUCTS for commercial use in
         humans, if after 5 (five) years from the EFFECTIVE DATE, OXYCELL has
         not taken the necessary steps for the commercialization of the CONTRACT
         PRODUCTS, and cannot provide any reasonable justification for such
         failure the CNRS may terminate the present Agreement in accordance with
         the procedure set out in Article 13.2 above.

13.4     Oxycell may terminate as of right without any judicial formalities, the
         present Agreement at each anniversary date of the EFFECTIVE DATE,
         subject to a prior written notification to CNRS, at least 3 month
         before the above anniversary date. OXYCELL shall be liable for a
         payment of any monies due prior to the termination date.

13.5     Should the present Agreement expire or be terminated OXYCELL agrees not
         to use or allow any direct or indirect use of the Valid Claims for
         CONTRACT PATENTS until the expiration of the last of the VALID CLAIMS
         for such patents. However, OXYCELL shall have the right to dispose of
         existing inventory for 180 (one hundred and eighty) days following any
         such expiration or termination. Furthermore, each PARTY agrees to
         return or destroy all proprietary or confidential information,
         material, and documents that it has received from the other PARTY and
         not to conserve any copies for any purposes whatsoever.

                                      -16-
<PAGE>   17

13.6     Upon termination of the present Agreement and subject to the provisions
         of Article 2 all rights in and to the Contract Products shall revert to
         CNRS at no cost to CNRS, provided that CNRS shall enter into a direct
         license agreement with the SUBLICENSEE in the event the sublicensee
         cures any payment defaults and agrees to directly assume the
         obligations of Oxycell or any Affiliate under the present Agreement and
         to make all payments directly to CNRS. In this connection CNRS agrees
         to promptly issue, from time to time, upon written request, estoppel
         certificates in favor of Oxycell, AFFILIATES, sublicensees or potential
         sublicensees setting forth the status of the present Agreement and, if
         in default, the conditions required to cure the same.

Article 14 - ENTIRE AGREEMENT

14.1     The present Agreement expresses the entire understanding of the
         PARTIES. No general or specific condition appearing in any document
         sent or given by the PARTIES can be integrated in the present
         Agreement.

14.2     The present Agreement replaces any previous agreements and may only be
         modified or renewed by an amendment signed by duly authorized
         representatives of the PARTIES.

14.3     It is hereby agreed that the relationship established by the PARTIES in
         the present Agreement does not confer any other rights than those set
         out hereof. It is expressly agreed that the present Agreement does not
         confer any rights to OXYCELL outside the CONTRACT FIELD, nor rights to
         any patents other than the CONTRACT PATENTS or to any know how other
         than the CONTRACT KNOW-HOW.

Article 15 - HEADINGS

         In the event of difficulties of interpretation between any of the
         headings preceding the clauses and any one of the clauses, the headings
         shall be ignored.

Article 16 - INVALIDITY OF A CLAUSE

         Should one or more provisions of the present Agreement be held to be
         invalid by law or regulation - and in particular the laws or
         regulations of the European Union or based on a definitive decision of
         a competent court, all the other provisions shall remain in full effect
         and the PARTIES shall make the necessary modifications without delay
         while respecting, as closely as possible, the spirit of the present
         Agreement at the moment of signature.

                                      -17-
<PAGE>   18

Article 17 - WAIVER

         The failure of one of the PARTIES to assert a breach of the present
         Agreement by the other PARTY shall not be interpreted as a waiver of
         said obligation.

Article 18 - DISPUTES - GOVERNING LAW

18.1     The laws of France shall govern the present Agreement.

18.2     In the event that a difficulty arises in the interpretation or
         execution of the present Agreement, the PARTIES shall try to settle
         their differences out of court within a limited period of 3 months as
         from the issuance of a written notice by either party of a dispute.

18.3     In case of persistent disagreement after the 3 months settlement
         period, the competent French courts shall have sole jurisdiction to
         settle any disputes in respect of the interpretation and/or performance
         of the Agreement.

18.4     The present Article shall remain in effect regardless of the expiration
         or termination of the present Agreement.

Article 19 - REGISTRATION AT THE REGISTRE NATIONAL DES BREVETS - FISCAL
REGISTRATION

19.1     The present Agreement may be registered at the Registre National des
         Brevets, which is controlled by the Institut National de Propriete
         Industrielle, and each National Patent Office for the purpose of
         registering the CONTRACT PATENTS; the fees of said registrations to be
         paid by the OXYCELL.

19.2     Any fiscal registrations of the present Agreement shall be performed by
         OXYCELL at its sole expense.

Article 20 - LANGUAGE

         The present Agreement has been established in two versions, one in
         French and one in English. In case of difficulties of interpretation,
         the French version shall prevail.

Article 21 - NOTIFICATIONS

         All notifications for the present Agreement shall be sent by registered
         letter with acknowledgment of receipt to the PARTY for which the notice
         is intended at the following address:

                                      -18-
<PAGE>   19

         For the CNRS:
         CNRS
         Delegation aux Entreprises
         3 rue Michel-Ange
         75794 Paris Cedex 16
         France

         For OXYCELL:
         GLOBAL OXYCELL INC.
         Dr. Bart CHERNOW
         1 East Broward Blvd.
         Suite 1701
         Fort Lauderdale
         Florida
         3301
         USA

In Paris                                              In Fort Lauderdale
the 5th day of June, 2000                             the 23rd day of May, 2000

In three copies including one for the Institut National de la Propriete
Industrielle and one for the contracting PARTIES.

---------------------------                  ---------------------------
Mrs. Catherine BRECHIGNAC                    Dr. Bart CHERNOW
General Manager of CNRS                      Chief Executive Officer of GLOBAL
                                             OXYCELL

                                      -19-
<PAGE>   20

                                    EXHIBIT A
                                CONTRACT PATENTS

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------
  COUNTRY      FILING        FILING    VIA     PROC     PUB.       PUB       ISSUE     ISSUE         EXP.
              N(DEGREE)       DATE                      DATE     N(DEGREE)   DATE     N(DEGREE)     DATE
------------------------------------------------------------------------------------------------------------
<S>           <C>           <C>        <C>     <C>    <C>        <C>        <C>       <C>         <C>
    FR         96 09557     30/07/96    BN     DLV    06/02/98    2751972   04/09/98  96 09557    30/07/16
------------------------------------------------------------------------------------------------------------
    JP         97530677     28/02/97   PCT     DEP
------------------------------------------------------------------------------------------------------------
    CA         2248186      28/02/97   PCT     DEP                                                28/02/17
------------------------------------------------------------------------------------------------------------
    MX          986892      28/02/97   PCT     DEP
------------------------------------------------------------------------------------------------------------
    BR                      28/02/97   PCT     DEP                                                28/02/12
------------------------------------------------------------------------------------------------------------
    NO          983691      28/02/97   PCT     DEP                                                28/02/17
------------------------------------------------------------------------------------------------------------
    KR         98706784     28/02/97   PCT     DEP                                                28/02/12
------------------------------------------------------------------------------------------------------------
    HU         P9902465     28/02/97   PCT     DEP                                                28/02/17
------------------------------------------------------------------------------------------------------------
    IL          125926      28/02/97   PCT     DEP                                                28/02/17
------------------------------------------------------------------------------------------------------------
    EP        97907154.5    28/02/97   PCT     DEP                                                28/02/17
------------------------------------------------------------------------------------------------------------
    AU         9719304      28/02/97   PCT     DEP                                                28/02/13
------------------------------------------------------------------------------------------------------------
    US        09/125825     28/02/97   PCT     DEP
------------------------------------------------------------------------------------------------------------
    WO        FR97/00364    28/02/97   PCT     PUB    04/09/97  WO97/31935                        28/10/99
------------------------------------------------------------------------------------------------------------
    CZ          982772      28/02/97   PCT     DEP
------------------------------------------------------------------------------------------------------------
    SK         98 1182      28/02/97   PCT     DEP
------------------------------------------------------------------------------------------------------------
</TABLE>

                                      -20-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}]]